Payment overview · 2025
General Payments
$1,083.03
48 reported records · 17 companies
Healthcare provider profile · identity verified
Usha Natesan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SALISBURY, MD · NPI 1336160290
Verified facts
What the public records show
CMS Open Payments records show Usha Natesan, M.D. received $1,083.03 in general payments during 2025 across 48 reported records.
Amgen Inc. accounted for 22.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Jardiance, Ozempic, Rybelsus, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ubrelvy by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 269 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $248.03 | 22.9% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $173.48 | 16.0% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $113.68 | 10.5% | 6 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $99.99 | 9.2% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $97.63 | 9.0% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.91 | 3.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.84 | 3.5% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $37.76 | 3.5% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $37.30 | 3.4% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $34.51 | 3.2% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $33.96 | 3.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.86 | 2.9% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $27.33 | 2.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.08 | 1.9% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.47 | 1.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.38 | 1.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.82 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $938.04 | 46 |
| Education | $144.99 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $237.69 | 7 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $97.63 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $93.82 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $93.82 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $63.44 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $56.32 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $50.24 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $50.24 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $40.91 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $37.76 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $37.30 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $34.66 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $34.51 | 2 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $33.96 | 2 | 2025 |
Source payment records
|
|||||
| AMS 700 Normalized: ams 700 |
Device | Boston Scientific Corporation | $27.33 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $24.30 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $24.30 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.08 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $10.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 172 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 107 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 269 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
91 | 24 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
107 | 30 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
172 | 44 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
107 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
269 | 50 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
172 | 44 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
38 | 38 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 692 | 195 |
| Levothyroxine Sodium | Levothyroxine Sodium | 499 | 129 |
| Amlodipine Besylate | Amlodipine Besylate | 477 | 132 |
| Atorvastatin Calcium | Atorvastatin Calcium | 454 | 127 |
| Pantoprazole Sodium | Pantoprazole Sodium | 408 | 118 |
| Metoprolol Succinate | Metoprolol Succinate | 362 | 98 |
| Potassium Chloride | Potassium Chloride | 351 | 99 |
| Losartan Potassium | Losartan Potassium | 342 | 103 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 295 | 105 |
| Lisinopril | Lisinopril | 286 | 73 |
| Gabapentin | Gabapentin | 275 | 82 |
| Ozempic | Semaglutide | 269 | 50 |
| Montelukast Sodium | Montelukast Sodium | 267 | 79 |
| Fluticasone Propionate | Fluticasone Propionate | 262 | 99 |
| Simvastatin | Simvastatin | 246 | 68 |
| Famotidine | Famotidine | 227 | 68 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 226 | 64 |
| Ezetimibe | Ezetimibe | 207 | 54 |
| Metformin Hcl | Metformin Hcl | 190 | 51 |
| Omeprazole | Omeprazole | 185 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 180 | 56 |
| Sertraline Hcl | Sertraline Hcl | 174 | 48 |
| Eliquis | Apixaban | 172 | 44 |
| Prednisone | Prednisone | 170 | 98 |
| Metformin Hcl Er | Metformin Hcl | 169 | 50 |
| Meloxicam | Meloxicam | 163 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 157 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 157 | 48 |
| Trazodone Hcl | Trazodone Hcl | 157 | 46 |
| Furosemide | Furosemide | 155 | 50 |
| Azithromycin | Azithromycin | 152 | 133 |
| Carvedilol | Carvedilol | 150 | 35 |
| Torsemide | Torsemide | 147 | 47 |
| Donepezil Hcl | Donepezil Hcl | 141 | 32 |
| Alprazolam | Alprazolam | 139 | 51 |
| Celecoxib | Celecoxib | 139 | 59 |
| Metoprolol Tartrate | Metoprolol Tartrate | 135 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 134 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 131 | 31 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 128 | 29 |
| Alendronate Sodium | Alendronate Sodium | 122 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 119 | 36 |
| Tramadol Hcl | Tramadol Hcl | 119 | 45 |
| Clonazepam | Clonazepam | 116 | 24 |
| Jardiance | Empagliflozin | 107 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 63 |
| Memantine Hcl | Memantine Hcl | 100 | 17 |
| Clonidine Hcl | Clonidine Hcl | 99 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 96 | 58 |
| Allopurinol | Allopurinol | 93 | 19 |
| Synthroid | Levothyroxine Sodium | 91 | 24 |
| Atenolol | Atenolol | 90 | 25 |
| Spironolactone | Spironolactone | 89 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 87 | 72 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 80 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 80 | 69 |
| Cephalexin | Cephalexin | 74 | 59 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 74 | 22 |
| Mirtazapine | Mirtazapine | 73 | 23 |
| Valsartan | Valsartan | 69 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 23 |
| Fluconazole | Fluconazole | 66 | 43 |
| Glimepiride | Glimepiride | 66 | 14 |
| Labetalol Hcl | Labetalol Hcl | 63 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 63 | 14 |
| Cholestyramine | Cholestyramine (With Sugar) | 61 | 31 |
| Doxycycline Hyclate | Doxycycline Hyclate | 61 | 53 |
| Amitriptyline Hcl | Amitriptyline Hcl | 59 | suppressed |
| Methylprednisolone | Methylprednisolone | 59 | 55 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 12 |
| Glipizide Er | Glipizide | 57 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 14 |
| Nystatin | Nystatin | 56 | 28 |
| Ibuprofen | Ibuprofen | 53 | 19 |
| Levetiracetam | Levetiracetam | 53 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 14 |
| Nifedipine Er | Nifedipine | 51 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 49 | 11 |
| Fenofibrate | Fenofibrate | 48 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 48 | 16 |
| Valacyclovir | Valacyclovir Hcl | 48 | 25 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 47 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 46 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 45 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | 13 |
| Meclizine Hcl | Meclizine Hcl | 45 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 45 | 16 |
| Metronidazole | Metronidazole | 44 | 41 |
| Amiodarone Hcl | Amiodarone Hcl | 42 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 42 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 39 |
| Clonidine | Clonidine | 41 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 20 |
| Repatha Sureclick | Evolocumab | 41 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 40 | 32 |
| Estradiol | Estradiol | 40 | 20 |
| Lovastatin | Lovastatin | 40 | 12 |
| Naproxen | Naproxen | 40 | 24 |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 39 | suppressed |
| Lorazepam | Lorazepam | 39 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Ondansetron Odt | Ondansetron | 38 | 30 |
| Paxlovid | Nirmatrelvir/Ritonavir | 38 | 38 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | suppressed |
| Entresto | Sacubitril/Valsartan | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | 12 |
| Febuxostat | Febuxostat | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Pregabalin | Pregabalin | 34 | 13 |
| Temazepam | Temazepam | 33 | suppressed |
| Baclofen | Baclofen | 31 | 11 |
| Clindamycin Hcl | Clindamycin Hcl | 31 | 29 |
| Levofloxacin | Levofloxacin | 31 | 29 |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | 12 |
| Sucralfate | Sucralfate | 30 | 16 |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 29 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 29 | 24 |
| Ipratropium Bromide | Ipratropium Bromide | 27 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 21 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Klor-Con M20 | Potassium Chloride | 26 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | 12 |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Gemtesa | Vibegron | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Colchicine | Colchicine | 20 | 11 |
| Colesevelam Hcl | Colesevelam Hcl | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Livalo | Pitavastatin Calcium | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 16 |
| Risperidone | Risperidone | 19 | suppressed |
| Azathioprine | Azathioprine | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 18 | suppressed |
| Paroxetine Cr | Paroxetine Hcl | 18 | suppressed |
| Cefdinir | Cefdinir | 17 | 16 |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | 12 |
| Constulose | Lactulose | 16 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 11 |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 15 | 14 |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 13 | suppressed |
| Ubrelvy | Ubrogepant | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Hydroxyurea | Hydroxyurea | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 12 | suppressed |
| Demeclocycline Hcl | Demeclocycline Hcl | 11 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Oxazepam | Oxazepam | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,083.03 · 48 records | Amgen Inc. | ABRYSVO, AIRSUPRA, AMS 700, AMYVID, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FUROSCIX, GEMTESA, JARDIANCE, KISUNLA, KRYSTEXXA, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, TRINTELLIX, UBRELVY, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error